Orphazyme announces Interim Report First Half 2019
August 28, 2019 01:03 ET
|
ORPHAZYME A/S
Company announcement Orphazyme A/SNo....
Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital
August 27, 2019 15:14 ET
|
ORPHAZYME A/S
Company announcement Orphazyme A/SNo. 25/2019 Company Registration No. 32266355 Loan agreement to...
Orphazyme Interim Report First Half 2019 Presentation
August 21, 2019 06:23 ET
|
ORPHAZYME A/S
Investor news Orphazyme A/SCompany Registration No. 32266355 Copenhagen, Denmark, August...
Major shareholder announcement
August 05, 2019 12:20 ET
|
ORPHAZYME A/S
Company announcement No. 24/2019 Orphazyme...
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
July 29, 2019 14:18 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
New phantom share-based incentive program
July 29, 2019 11:19 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 22/2019 ...
New share-based incentive program
July 29, 2019 11:16 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 21/2019 ...
New incentive program for the Board of Directors of Orphazyme
July 29, 2019 11:11 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 20/2019 Company Registration No. 32266355 ...
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
July 26, 2019 10:35 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 19/2019Company Registration No. 32266355 ...
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
July 21, 2019 06:03 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...